Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK

References

• Gran JT, Husby G. Clinical, epidemiologic, and therapeutic aspects of ankylosing spondylitis. Curr Opin Rheumatol 1998;10:292–8
   PubMedGoogle Scholar
• Boonen A, van der Heijde D, Landewe R. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003;62:732–40
   PubMed Web of Science ®Google Scholar
• Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology 2004;43:1158–66
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNFα therapy. Ann Rheum Dis 2001;60:iii58–61
   Google Scholar
• Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817–24
   PubMed Web of Science ®Google Scholar
• Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423–32
   PubMed Web of Science ®Google Scholar
• Keat A. BSR guideline for prescribing TNF alpha blockers in adults with ankylosing spondylitis. The British Society for Rheumatology, 2004
   Google Scholar
• Rostom A, Dubé C, Jolicoeur E, et al. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventative pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment, Technology overview no. 12, 2004
   Google Scholar
• Jenkins JK, Seligman PJ. FDA decision memo – analysis and recommendations for agency action – COX-2 selective and non-selective NSAIDs. 2005. Available from http://www.fda.gov/cder/drug/infopage/cox2/NSAIDdecisionMemo.pdf [Last accessed 28 July 2006]
   Google Scholar
• van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205–15
   PubMed Web of Science ®Google Scholar
• Ramey DR, Watson JD, Yu CB, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21:715–22
   PubMed Web of Science ®Google Scholar
• Laine L, Reicin AS, Yu Q, et al. COX-2 selective inhibitors rofecoxib and etoricoxib decrease serious lower gastrointestinal clinical events compared to non-selective NSAIDs: a meta-analysis. The 11th Asia Pacific League of Associations for Rheumatology Congress. Korea, Jeju, September 11–15, 2004, pp. 85–6
   Google Scholar
• Curtis SP, Mukhopadhyay S, Ramey D, et al. Cardiovascular safety summary associated with the etoricoxib development program. Arthritis Rheum 2003;48:S35–750
   PubMedGoogle Scholar
• Moore RA, Phillips CJP, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004;22:643–60
   PubMed Web of Science ®Google Scholar
• MediPlus IMS UK, 2003
   Google Scholar
• Bird HA, Le Gallez P, Astbury C. A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. Pharmatherapeutica 1986;4:457–62
   PubMedGoogle Scholar
• Batlle-Gualda E, Figueroa M, Ivorra J, et al. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 1996;23:1200–6
   Google Scholar
• Khan MA. A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. J Rheumatol 1987;14:118–23
   PubMed Web of Science ®Google Scholar
• Santo JE, Queiroz MV. Oxaprozin versus diclofenac sodium in the treatment of ankylosing spondylitis. J Int Med Res 1988;16:150–6
   PubMed Web of Science ®Google Scholar
• Schwarzer AC, Cohen M, Arnold MH, et al. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Curr Med Res Opin 1990;11:648–53
   PubMed Web of Science ®Google Scholar
• McKenna F. Efficacy of diclofenac/misoprostol vs. diclofenac in the treatment of ankylosing spondylitis. Drugs 1993;45 (Suppl 1):24–30
   Google Scholar
• Villa Alcazar LF, de Buergo M, Rico LH, et al. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996;23:1194–9
   Google Scholar
• Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169–82
   PubMed Web of Science ®Google Scholar
• Moore RA, Phillips CJ, Pellissier JM, et al. Health economic comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. Journal of Medical Economics 2001;4:1–17
   Google Scholar
• Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998;12:135–40
   PubMed Web of Science ®Google Scholar
• Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 2003;49:483–7
   PubMed Web of Science ®Google Scholar
• Ware JE. SF-36: the SF-36 community. Available from http://www.sf-36.org/tools/sf36.shtml#CONSTRUCT [Last accessed 10 May 2004]
   Google Scholar
• Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Making 2001;21: 105–12
   Google Scholar
• Marzo-Ortega H, McGonagle D, O’Connor P, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112–7
   Google Scholar
• Boonen A, Van Der Heijde, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis. A comparison among three European countries. Ann Rheum Dis 2002;61:429–37
   PubMed Web of Science ®Google Scholar
• Monthly digest of statistics. December 2004, No 708. UK Office for National Statistics: Palgrave Macmillan
   Google Scholar
• Government Actuary’s Department (GAD) interim life tables 1999–2001, UK. Available from http://www.gad.gov.uk/Life_Tables/Interim_life_tables.htm [Last accessed 10 Mar 2005]
   Google Scholar
• Robertson LP, Davis MJ. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology 2004;43:1565–8
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K, editors. Making decision models probabilistic. Decision modelling for health economic evaluation, pp 77–120. Oxford: Oxford University Press, 2006
   Google Scholar
• Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79
   PubMed Web of Science ®Google Scholar
• Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004;26:70–83
   PubMed Web of Science ®Google Scholar
• Boonen A, Chorus A, Miedema H, et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353–8
   PubMed Web of Science ®Google Scholar
• Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003;49:283–92
   PubMedGoogle Scholar
• Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment of arthritis. Am J Med 1988;84:315–22
   PubMedGoogle Scholar
• Maetzel A, Bosi Ferraz M, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arth Rheum 1998;41:16–25
   PubMed Web of Science ®Google Scholar
• Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990;66:639–46
   Google Scholar
• Singh G, Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective – 1997. Arthritis, rheumatism, and aging medical information system. J Rheum 1998;51:8–16
   Google Scholar
• de Pouvourville G. The economic consequences of NSAID-induced gastropathy: The French context. Scand J Rheumatol Suppl 1992;96:49–53
   PubMedGoogle Scholar
• Jönsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Tech Assess Health Care 1992;8:234–44
   PubMedGoogle Scholar
• Gabriel SE, Matteson EL. Economic and quality of life impact of NSAIDs in rheumatoid arthritis: a conceptual framework and selected literature review. Pharmacoeconomics 1995;8:479–90
   PubMed Web of Science ®Google Scholar
• Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996;11:461–9
   PubMed Web of Science ®Google Scholar
• Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990;264:41–7
   Google Scholar
• Gabriel SE, Campion ME, O’Fallon WM. Patient preferences for nonsteroidal antiinflammatory drug-related gastrointestinal complications and their prophylaxis. J Rheum 1993;20:258–61
   Google Scholar
• Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for non-steroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arth Rheum 1993;36:447–59
   Google Scholar
• Johnson RE, Hornbrook MC, Hooker RS, et al. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organization. Pharmacoeconomics 1997;12:76–88
   Google Scholar
• Kong SX, Hatoum HT, Zhao SZ, et al. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am J Manag Care 1998;4:399–409
   PubMed Web of Science ®Google Scholar
• Curtis L, Netten A. Unit costs of health and social care 2004. Personal Social Services Research Unit, University of Kent, Canterbury, UK, 2004
   Google Scholar